Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 5% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Reduction of intracranial pressure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Promotion of diuresis in acute renal failure (off-label),Adjunctive therapy in drug intoxication (off-label)
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 m L of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
The terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal renal function. This can be prolonged to 6-12 hours in patients with renal impairment, requiring dose adjustment.
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
Primarily excreted unchanged by the kidneys (glomerular filtration). Minimal hepatic metabolism.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Mannitol is excreted primarily by the kidneys via glomerular filtration, with approximately 80% of an administered dose appearing unchanged in urine within 3 hours. Less than 10% undergoes tubular reabsorption; negligible biliary or fecal elimination (<1%).
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
Essentially negligible; protein binding is less than 1% and not bound to any specific plasma proteins.
Negligible (<0.1%); no specific binding proteins.
Volume of distribution is approximately 0.5 L/kg, indicating distribution primarily in extracellular fluid. Mannitol does not readily cross cell membranes, so its distribution is limited to the extracellular space.
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
Bioavailability is 100% after intravenous administration, as it is the only route of clinical use. Oral administration has negligible absorption (<1%) and is used only for bowel preparation, but no systemic bioavailability is expected.
IV: 100%; oral: <10% due to poor absorption.
Contraindicated in anuria. For GFR <10 m L/min: avoid use. GFR 10-50 m L/min: reduce dose by 50% and monitor serum osmolarity. GFR >50 m L/min: no adjustment.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
No specific adjustment for Child-Pugh class. Use with caution in severe hepatic impairment due to risk of fluid overload.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
Intravenous infusion. Initial dose: 0.25-1 g/kg given over 30-60 minutes. May repeat every 8-12 hours. Maximum total daily dose: 2 g/kg.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Start at lower end of dosing range (50 g) due to age-related renal decline. Monitor for hypovolemia, electrolyte disturbances, and pulmonary edema. Avoid use in patients with heart failure.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
No FDA black box warning.
None
May cause electrolyte imbalances (hyponatremia, hypernatremia, hypokalemia),Risk of volume expansion and heart failure in patients with cardiac impairment,Monitor renal function and urine output; may precipitate acute renal failure in pre-renal azotemia,Intravenous use: administer via large vein to avoid phlebitis,Avoid extravasation (can cause tissue necrosis),Use with caution in patients with pulmonary congestion or severe dehydration
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Anuria due to severe renal disease,Pulmonary congestion or edema,Active intracranial hemorrhage (unless in the setting of craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
Avoid excessive salt intake as it may counteract the diuretic effect. No specific food restrictions, but maintain a balanced diet as tolerated. Monitor fluid intake as directed by healthcare provider.
No significant food interactions; maintain adequate hydration unless contraindicated.
Osmitrol (mannitol) is classified as FDA Pregnancy Category C. Animal reproduction studies have not been conducted with mannitol. It is not known whether mannitol can cause fetal harm when administered to a pregnant woman. Mannitol crosses the placenta. Use during pregnancy only if clearly needed and potential benefits justify potential risks to the fetus. First trimester: Insufficient data to assess risk; theoretical risk of osmotic effects. Second and third trimesters: May cause fetal dehydration and electrolyte imbalances. High doses may induce uterine contractions.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
Mannitol is not systemically absorbed after oral administration. There are no reports of mannitol in breast milk. However, due to potential for excretion and lack of data, caution is advised. M/P ratio is unknown. Intravenous mannitol may be excreted into breast milk in low amounts; theoretical risk of osmotic diarrhea in the infant. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
Pregnancy may alter pharmacokinetics but specific dose adjustments for mannitol in pregnancy are not established. Increased plasma volume and GFR in pregnancy may enhance mannitol clearance, potentially requiring dose escalation to achieve desired osmotic effect. However, due to risks of volume overload and electrolyte disturbances, use lowest effective dose and carefully titrate based on clinical response and laboratory monitoring. No specific trimester-based dose adjustments are defined.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
Osmitrol 5% (mannitol) is an osmotic diuretic used to reduce intracranial pressure and cerebral edema. Administer via IV infusion with an in-line filter to prevent crystallization. Monitor serum osmolality; stop infusion if osmolality exceeds 320 m Osm/L to avoid acute kidney injury. Use cautiously in patients with pulmonary edema or congestive heart failure due to fluid overload risk. May cause transient hypervolemia followed by diuresis.
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
This medication is given intravenously to reduce brain swelling or pressure inside the eye.,You may experience increased thirst, headache, or frequent urination during treatment.,Report any chest pain, difficulty breathing, or swelling in your legs immediately.,Drink fluids only as directed by your healthcare provider; do not consume extra water.,You may need blood tests to monitor your kidney function and electrolyte levels.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 5% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% IN PLASTIC CONTAINER, answered by our medical review team.
OSMITROL 5% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.. MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 5% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 5% IN WATER IN PLASTIC CONTAINER is: Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 m L of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.. The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 5% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 5% IN WATER IN PLASTIC CONTAINER is classified as Category C. Osmitrol (mannitol) is classified as FDA Pregnancy Category C. Animal reproduction studies have not been conducted with mannitol. It is not known whether mannitol can cause fetal h. MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.